Small biotechs in early development of cell therapies are often surprised by the strictness of commercial manufacturing standards. That’s the view of Luděk Sojka, PhD, CEO of contract developer and ...
This article outlines common CMC problems that are obstacles that steal momentum and create costly detours in the development ...
The launch of the GMP PSXi013 iPSC Master Cell Bank marks a pivotal moment in Pluristyx's ongoing mission to accelerate the development of stem cell therapies. By providing a high-quality, low-passage ...
GAINESVILLE, Fla., May 28, 2020 /PRNewswire/ -- Arranta Bio ("Arranta"), the leading microbiome contract development and manufacturing organization (CDMO), today announced completion of its process ...
Pheast Therapeutics is using a platform-based approach to scaling manufacturing for its anti-CD24 checkpoint inhibitor, PHST001. By compressing the chemistry, manufacturing, and control (CMC) steps ...
SEONGDONG-GU, SEOUL, SOUTH KOREA, January 5, 2023 / EINPresswire.com / -- MDimune Inc., a Korean biotech company developing BioDrone™ platform technology based on cell-derived vesicles (CDVs), ...
VANCOUVER, British Columbia, Jan. 21, 2025 (GLOBE NEWSWIRE) -- HYTN Innovations Inc. (CSE: HYTN, FSE: 85W0, OTC PINK: HYTNF) (“HYTN” or the “Company”), a company specializing in pharmaceutical-grade ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback